Press Release: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) ("Ocuphire"), a clinical-st

Dow JonesApr 22 08:00 ET

Ocuphire Pharma Incentivizes Director Pepose With Stocks and Options

TipRanksApr 17 16:32 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%

BenzingaApr 11 16:31 ET

Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment

Ocuphire Pharma (OCUP) enrolled the first patient in the phase 3 trial of its Phentolamine Ophthalmic Solution 0.75% for the treatment of decreased visual acuity under low light conditions following k

MT NewswiresApr 11 14:28 ET

Express News | First Patient Enrolled in Lynx-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (Ps) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

Moomoo 24/7Apr 11 10:03 ET

Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)

TipRanksApr 2 07:20 ET